MT 1011
Alternative Names: MT-1011Latest Information Update: 23 Jun 2025
At a glance
- Originator Shaanxi Micot Technology Co
- Class Cardiovascular therapies; Coagulants; Peptides; Small molecules; Vascular disorder therapies
- Mechanism of Action Factor Xa modulators; Thrombin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Unspecified
- No development reported Cardiovascular disorders; Cerebrovascular disorders
Most Recent Events
- 17 Jun 2025 Phase-I clinical trials in Unspecified (In volunteers, In adults) in China (Parenteral) (NCT07024160)
- 28 Oct 2024 No recent reports of development identified for research development in Cardiovascular-disorders in China (Parenteral)
- 28 Oct 2024 No recent reports of development identified for research development in Cerebrovascular-disorders in China (Parenteral)